Why the Purifloh share price is up 500% over the past year

What's behind the incredible performance of Purifloh Limited (ASX:PO3)?

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Purifloh Limited (ASX: PO3) share price is up from 78 cents this time last year to $4.75 today, although many ASX share market investors won't have heard of this company that is in the air and water purification technology space.

The company changed its name from Water Resources Group Limited which it held since listing in 2010, to Purifloh Limited in April 2018, with the ticker PO3 being selected as O3 is the ozone radical of oxygen.

However, what really sent the Purifloh share price into orbit was news on November 7 2018 that the company had managed to secure a $9.6 million investment via the placement of 4 million shares at $2.4o each. Prior to this announcement the stock changed hands for just 50 cents.

According to Purifloh the investor is US based Upjohn Laboratories LLC that is the family run investment vehicle of businessman Mr Bill Parfet. Upjohn now owns 16.8% of Purifloh in total and has agreed to establish a subsidiary in the US to help commercially develop Purifloh's Free Radical Generator Technology.

For the quarter ending September 30 2018 Purifloh posted no revenue and a cash outflow of $117,000, which makes its stellar share price performance curious, with the company now boasting a market value of $145 million according to Commsec.

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Winning woman smiles and holds big cup while losing woman looks unhappy with small cup
Share Gainers

Here are the top 10 ASX 200 shares today

It was a dour Tuesday for ASX investors.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why Brightstar Resources, Immutep, Pilbara Minerals, and Race Oncology shares are roaring higher

These shares are having a strong session on Tuesday. But why?

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Healthcare Shares

Guess which ASX 300 healthcare share is rocketing 28% on global expansion news

Investors are piling into the ASX 300 healthcare share on Tuesday. Let’s see why.

Read more »

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a Garfield kind of Monday for investors.

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Share Gainers

Why Artrya, Clinuvel, Imugene, and Pilbara Minerals shares are storming higher today

These shares are starting the week in a positive fashion. But why?

Read more »

An old-fashioned panel of judges each holding a card with the number 10
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the trading week this Friday.

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Up 680% since July, here's why 2025 was a breakout year for this hot ASX stock

With consistent contract wins, FDA clearance, and backing from Pro Medicus, 4D Medical is showing that there is a commercial…

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Share Gainers

4 ASX 200 stocks smashing the benchmark this week

Investors have been piling into these four ASX 200 stocks this week. Let’s see why.

Read more »